MTOR and acute lymphoblastic leukemia: Utilizing establishing PDX models from drug-resistant patients, researchers identified mutation sites such as MET that led to cetuximab resistance.183 Silic-Benussi et al. revealed that, in the context of T-cell acute lymphoblastic leukemia (T-ALL), mTOR pathway activation led to drug resistance to glucocorticoid because of an insufficient level of ROS.